BRAF and cancer: Furthermore, the activation of autophagy may also promote drug resistance in cancer cells treated with the BRAF inhibitor (BRAFi) vemurafenib, as the biopsies from BRAFi-resistant melanoma patients exhibited increased levels of autophagy compared with baseline70.